tiprankstipranks
Trending News
More News >
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
US Market

Aytu BioScience (AYTU) Earnings Dates, Call Summary & Reports

Compare
1,242 Followers

Earnings Data

Report Date
Sep 25, 2025
TBA Not Confirmed
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.31
Last Year’s EPS
-0.82
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 14, 2025
|
% Change Since: 17.78%
|
Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth, positive net income, and successful strategic initiatives. Although there was a decline in gross margin due to higher cost inventory, the overall sentiment remains positive due to the company's operational efficiency and the success of the Aytu RxConnect platform.
Company Guidance
In the Aytu BioPharma fiscal 2025 Q3 earnings call, the company reported a 32% increase in total revenue, driven by a 25% growth in the ADHD portfolio and a 77% growth in the pediatric portfolio. The implementation of cost reduction initiatives led to a $1.6 million decrease in operating expenses, resulting in a $2.4 million income from operations. This quarter marked the second time the company achieved positive income from operations and the third consecutive quarter of positive net income, totaling $4 million. Earnings per share were $0.65, contrasting with a $0.52 loss per share in the previous year. Adjusted EBITDA reached $3.9 million, up from $0.9 million in the prior year. The company highlighted its strategic focus on leveraging the Aytu RxConnect platform and its CNS-focused sales team to drive future growth through potential in-licensed or acquired products.
Significant Revenue Growth
Total revenue grew by 32% year-over-year, led by a 25% increase in the ADHD portfolio and a 77% increase in the pediatric portfolio.
Positive Income from Operations
Achieved income from operations of $2.4 million, marking the second quarter of positive income from operations in the company's history.
Net Income Improvement
Net income was $4 million, compared to a $2.9 million loss in the same quarter last year, translating to basic earnings per share of $0.65.
Adjusted EBITDA Growth
Adjusted EBITDA increased to $3.9 million from $0.9 million a year ago.
Operational Efficiency
Operating expenses decreased by $1.6 million, reflecting effective cost reduction initiatives.
Successful Strategic Initiatives
The company halted clinical development, wound down its Consumer Health business, outsourced manufacturing, and refinanced its long-term note.
Aytu RxConnect Platform Success
Aytu RxConnect was credited with contributing to revenue growth and providing a network of about 1,000 pharmacies that support patient access.

Aytu BioScience (AYTU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

AYTU Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Sep 25, 2025
2025 (Q4)
0.31 / -
-0.82
May 14, 2025
2025 (Q3)
-0.17 / 0.20
-0.52138.46% (+0.72)
Feb 12, 2025
2025 (Q2)
-0.28 / -0.28
-0.04-600.00% (-0.24)
Nov 13, 2024
2025 (Q1)
-0.34 / -0.20
-1.4886.49% (+1.28)
Sep 26, 2024
2024 (Q4)
-0.45 / -0.82
-0.59-38.98% (-0.23)
May 15, 2024
2024 (Q3)
-0.64 / -0.52
-1.9373.06% (+1.41)
Feb 14, 2024
2024 (Q2)
-0.25 / -0.04
-2.1598.14% (+2.11)
Nov 14, 2023
2024 (Q1)
-0.04 / -1.48
-1.2-23.33% (-0.28)
Sep 27, 2023
2023 (Q4)
-0.95 / -0.59
-9.893.98% (+9.21)
May 11, 2023
2023 (Q3)
-0.63 / -1.93
-35.894.61% (+33.87)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

AYTU Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2025
$1.35$2.59+91.85%
Feb 12, 2025
$1.39$1.38-0.72%
Nov 13, 2024
$1.74$1.55-10.92%
Sep 26, 2024
$2.85$2.36-17.19%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on Sep 25, 2025, TBA Not Confirmed.
    What is Aytu BioScience Inc (AYTU) earnings time?
    Aytu BioScience Inc (AYTU) earnings time is at Sep 25, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is AYTU EPS forecast?
          AYTU EPS forecast for the fiscal quarter 2025 (Q4) is 0.31.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis